MedTrace Logo

Phase II Trial of Allovectin-7® for Head and Neck Cancer

NCT00050388 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2008-06-24

No results posted yet for this study

Summary

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

Conditions

  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
  • Head and Neck Neoplasms
  • Carcinoma of the Head and Neck

Interventions

GENETIC

Allovectin-7®

Sponsors & Collaborators

  • Vical

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2002-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050388 on ClinicalTrials.gov